Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
复制标题
获取肿瘤组织以获得肿瘤浸润淋巴细胞用于诱导细胞治疗的外科考虑。
DOI：
10.1097/ppo.0000000000000608
复制
发表时间：
2022-07-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
肿瘤浸润性淋巴细胞过继细胞疗法(TILs)是一种研究中的细胞疗法，已在包括黑色素瘤在内的晚期实体瘤患者中证明了抗肿瘤效果。肿瘤浸润性淋巴细胞治疗包括手术切除患者的肿瘤，在克服肿瘤和肿瘤微环境引发的免疫抑制反应的条件下体外扩增TIL，给药淋巴去除方案，并将最终的TIL细胞治疗产品回输到患者体内，然后注射白细胞介素2以支持T细胞活性。外科医生在患者识别和肿瘤选择方面发挥着核心作用，这些步骤对于TIL细胞治疗的成功结果至关重要。TIL细胞治疗的商业化及其对患者的更广泛接触将需要外科医生、肿瘤学家和细胞治疗师之间的教育和合作。这篇综述强调了外科医生将在TIL细胞治疗的实施中发挥的独特作用，并作为一份关于患者选择和肿瘤切除方法的最佳实践的当代报告。
Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs), an investigational cellular therapy, has demonstrated antitumor efficacy in patients with advanced solid tumors, including melanoma. Tumor-infiltrating lymphocyte cell therapy involves surgical resection of a patient's tumor, ex vivo TIL expansion under conditions that overcome immunosuppressive responses elicited by the tumor and the tumor microenvironment, administration of a lymphodepleting regimen, and infusion of the final TIL cell therapy product back into the patient followed by interleukin 2 administration to support T-cell activity. The surgeon plays a central role in patient identification and tumor selection—steps that are critical for successful outcomes of TIL cell therapy. Commercialization of TIL cell therapy and its broader access to patients will require education and collaboration among surgeons, oncologists, and cellular therapists. This review highlights the unique role that surgeons will play in the implementation of TIL cell therapy and serves as a contemporary report of best practices for patient selection and tumor resection methods.
影响因子：
3.7
作者：
Ripley RT;Davis JL;Klapper JA;Mathur A;Kammula U;Royal RE;Yang JC;Sherry RM;Hughes MS;Libutti SK;White DE;Steinberg SM;Dudley ME;Rosenberg SA;Avital I
通讯作者：
Avital I